Sofosbuvir
성인

성인

Genotype 1

국내허가사항
  • HCV 단독감염: 본제+ 리바비린+ 페그인터페론 알파(12주) 또는 본제+ 리바비린(페그인터페론 알파 투여 부적격 또는 내약성이 없는 환자에 한해 사용, 24주)
  • HIV 동시감염: 본제+ 리바비린(24주)
Treatment-naïve, without cirrhosis or with compensated cirrhosis, in combination with Peginterferon + Ribavirin
  • BW <75 kg: 400 mg PO once daily + Peginterferon alfa + Ribavirin 500 mg PO twice daily x12w
  • BW ≥75 kg: 400 mg PO once daily + Peginterferon alfa + Ribavirin 600 mg PO twice daily x12w

Genotype 2

Without cirrhosis or with compensated cirrhosis, in combination with Ribavirin
  • BW <75 kg: 400 mg PO once daily + Ribavirin 500 mg PO twice daily x12w
  • BW ≥75 kg: 400 mg PO once daily + Ribavirin 600 mg PO twice daily x12w

Genotype 3

Without cirrhosis or with compensated cirrhosis, in combination with Ribavirin
  • BW <75 kg: 400 mg PO once daily + Ribavirin 500 mg PO twice daily x24w
  • BW ≥75 kg: 400 mg PO once daily + Ribavirin 600 mg PO twice daily x24w

Genotype 4

국내허가사항
  • HCV 단독감염: 본제+ 리바비린+ 페그인터페론 알파(12주) 또는 본제+ 리바비린(페그인터페론 알파 투여 부적격 또는 내약성이 없는 환자에 한해 사용, 24주)
  • HIV 동시감염: 본제+ 리바비린(24주)
Treatment-naïve, without cirrhosis or with compensated cirrhosis, in combination with Peginterferon + Ribavirin
  • BW <75 kg: 400 mg PO once daily + Peginterferon alfa + Ribavirin 500 mg PO twice daily x12w
  • BW ≥75 kg: 400 mg PO once daily + Peginterferon alfa + Ribavirin 600 mg PO twice daily x12w

Liver carcinoma, awaiting liver transplantation

Genotype 1-4, as component of combination antiviral treatment
  • BW <75 kg: 400 mg PO once daily for up to 48w or until transplantation + Ribavirin 500 mg PO twice daily
  • BW ≥75 kg: 400 mg PO once daily for up to 48w or until transplantation + Ribavirin 600 mg PO twice daily
No renal dose adjustment